Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series

Alemtuzumab—a monoclonal antibody targeting the CD52 glycoprotein expressed by most mature leucocytes—effectively decreases relapse rate and disability progression in early, relapsing–remitting multiple sclerosis (MS). However, secondary autoimmune disorders complicate therapy in nearly 50% of treat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eye (Lond)
Autores principales: Roos, Jonathan C. P., Moran, Carla, Chatterjee, V. Krishna, Jones, Joanne, Coles, Alasdair, Murthy, Rachna
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Conference Proceeding
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367353/
https://ncbi.nlm.nih.gov/pubmed/30498266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0282-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares